Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (3542)	4/23/2001 11:58:24 AM
From: Jibacoa	Read Replies (1) \| Respond to of 52153

In the mean time IMNR is up 69.63% on volume of 4,246,000 after the news that its REMUNE induces T helper cells response that corresponds with control of virus load.(That was the new "target" after they had discontinued REMUNE's trial on the "survival" target which triggered the stock drop from the 20 level).<g> CARLSBAD, Calif., April 23 /PRNewswire Interactive News Release/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced the publication of data today that suggest REMUNE(TM) (HIV-1 Immunogen), an investigational immune-based therapy, induces HIV specific (T helper cells) immune responses that correlate with control of virus (viral load, the amount of HIV in the bloodstream) in HIV-positive individuals. An analysis of a protocol defined random cohort from a Phase 3 study showed that patients treated with REMUNE demonstrated a statistically significant reduction in viral load at multiple time points throughout the trial, regardless of concomitant antiretroviral drug therapy. The results of the study appear in the April edition of HIV Medicine (www.BlackwellScientific.com), the official Journal of the European AIDS Clinical Society and the British HIV Association. siliconinvestor.com Bernard